Home/Pipeline/BA3071

BA3071

Solid tumors

Pre-clinicalIND-enabling studies

Key Facts

Indication

Solid tumors

Phase

Pre-clinical

Status

IND-enabling studies

Company

Imugene

About Imugene

Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Solid tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active